These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24499826)

  • 1. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
    Arizumi T; Ueshima K; Takeda H; Osaki Y; Takita M; Inoue T; Kitai S; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    J Gastroenterol; 2014 Dec; 49(12):1578-87. PubMed ID: 24499826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
    BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
    Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
    Tovoli F; Renzulli M; Negrini G; Brocchi S; Ferrarini A; Andreone A; Benevento F; Golfieri R; Morselli-Labate AM; Mastroroberto M; Badea RI; Piscaglia F
    Eur Radiol; 2018 Sep; 28(9):3611-3620. PubMed ID: 29633000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis.
    Arizumi T; Ueshima K; Iwanishi M; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Nishida N; Kitano M; Kudo M
    Dig Dis; 2015 Oct; 33(6):728-34. PubMed ID: 26488730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
    Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M; Bouattour M; Wassermann J; Bruno O; Dreyer C; Larroque B; Castera L; Vilgrain V; Belghiti J; Raymond E; Faivre S
    Oncologist; 2014 Apr; 19(4):394-402. PubMed ID: 24652387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
    Doemel LA; Chapiro J; Laage Gaupp F; Savic LJ; Kucukkaya AS; Petukhova A; Tefera J; Zeevi T; Lin M; Schlachter T; Jaffe A; Strazzabosco M; Patel T; Stein SM
    Eur Radiol; 2021 May; 31(5):2737-2746. PubMed ID: 33123796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    Wada Y; Takami Y; Tateishi M; Ryu T; Mikagi K; Saitsu H
    PLoS One; 2016; 11(1):e0146456. PubMed ID: 26745625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):733-9. PubMed ID: 25376291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Kaufmann S; Thaiss WM; Schulze M; Bitzer M; Lauer U; Nikolaou K; Horger M
    Acta Radiol; 2018 Jul; 59(7):765-772. PubMed ID: 28927298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    Salvaggio G; Furlan A; Agnello F; Cabibbo G; Marin D; Giannitrapani L; Genco C; Midiri M; Lagalla R; Brancatelli G
    Radiol Med; 2014 Apr; 119(4):215-21. PubMed ID: 24297581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    Shoji H; Yoshio S; Mano Y; Doi H; Sugiyama M; Osawa Y; Kimura K; Arai T; Itokawa N; Atsukawa M; Aoki Y; Fukai M; Taketomi A; Mizokami M; Kanto T
    Int J Cancer; 2017 Sep; 141(5):1011-1017. PubMed ID: 28555943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
    Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Satani M; Niizeki T; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Koga H; Torimura T;
    Oncotarget; 2016 Sep; 7(39):64400-64409. PubMed ID: 27462865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
    Fu S; Chen S; Liang C; Liu Z; Zhu Y; Li Y; Lu L
    Oncotarget; 2017 Jun; 8(23):37855-37865. PubMed ID: 27911268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma.
    Di Costanzo GG; Tortora R; Morisco F; Addario L; Guarino M; Cordone G; Falco L; Caporaso N
    Target Oncol; 2017 Feb; 12(1):61-67. PubMed ID: 27503006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.